Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KIAA1549-BRAF fusion
i
Other names:
KIAA1549, UPF0606 Protein KIAA1549, RP86, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
;
57670
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BRAF L485-P490 deletion (6)
BRAF amplification (1)
BRAF L485-P490 deletion (6)
BRAF amplification (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KIAA1549-BRAF fusion
Astrocytoma
KIAA1549-BRAF fusion
Astrocytoma
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
KIAA1549-BRAF fusion
Glioma
KIAA1549-BRAF fusion
Glioma
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
KIAA1549-BRAF fusion
Glioma
KIAA1549-BRAF fusion
Glioma
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
KIAA1549-BRAF fusion
Soft Tissue Sarcoma
KIAA1549-BRAF fusion
Soft Tissue Sarcoma
bevacizumab + sorafenib + temsirolimus
Sensitive: C3 – Early Trials
bevacizumab + sorafenib + temsirolimus
Sensitive
:
C3
bevacizumab + sorafenib + temsirolimus
Sensitive: C3 – Early Trials
bevacizumab + sorafenib + temsirolimus
Sensitive
:
C3
KIAA1549-BRAF fusion
Glioma
KIAA1549-BRAF fusion
Glioma
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
KIAA1549-BRAF fusion
Melanoma
KIAA1549-BRAF fusion
Melanoma
trametinib
Sensitive: C4 – Case Studies
trametinib
Sensitive
:
C4
trametinib
Sensitive: C4 – Case Studies
trametinib
Sensitive
:
C4
KIAA1549-BRAF fusion
Melanoma
KIAA1549-BRAF fusion
Melanoma
fotemustine
Sensitive: C4 – Case Studies
fotemustine
Sensitive
:
C4
fotemustine
Sensitive: C4 – Case Studies
fotemustine
Sensitive
:
C4
KIAA1549-BRAF fusion
Melanoma
KIAA1549-BRAF fusion
Melanoma
bevacizumab + sorafenib + temsirolimus
Sensitive: C4 – Case Studies
bevacizumab + sorafenib + temsirolimus
Sensitive
:
C4
bevacizumab + sorafenib + temsirolimus
Sensitive: C4 – Case Studies
bevacizumab + sorafenib + temsirolimus
Sensitive
:
C4
KIAA1549-BRAF fusion
Melanoma
KIAA1549-BRAF fusion
Melanoma
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
KIAA1549-BRAF fusion
Glioma
KIAA1549-BRAF fusion
Glioma
BVD-523
Sensitive: D – Preclinical
BVD-523
Sensitive
:
D
BVD-523
Sensitive: D – Preclinical
BVD-523
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login